EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C

Aya Ismail Abdelaziz, Eman Abdelsameea, Mohamed Abdel-Samiee, Samar E Ghanem, Sara A Wahdan, Doaa A Elsherbiny, Zeinab Zakaria, Samar S Azab iD

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01432-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Aya Ismail Abdelaziz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Interferons, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of HCV infection in Egypt has decreased following the introduction of direct-acting antiviral therapy. However, treatment response is influenced by various factors, particularly host immunogenetics such as IL-28B and FOXP3 polymorphisms. The current study examined the impact of SNPs in the FOXP3 gene promoter region on HCV-infected Egyptian patients, along with SNPs in the IL28B gene.This study involved 99 HCV patients who achieved SVR12 after a 12 week DAA treatment while 63 HCV patients experienced treatment failure. IL28B rs12979860 SNP was identified using real-time PCR, while IL28B rs8099917, FOXP3 rs3761548, and rs2232365 SNPs were analyzed using RFLP-PCR. Serum levels of IL28B and FOXP3 were quantified using ELISA technique in representative samples from both groups. The IL28B rs12979860 T > C ( P = 0.013) and FOXP3 rs2232365 A > G polymorphisms ( P = 0.008) were found to significantly increase the risk of non-response. Responders had higher IL28B serum levels ( P = 0.046) and lower FOXP3 levels ( P < 0.001) compared to non-responders. Regression analysis showed an association between IL28B rs12979860 and FOXP3 rs2232365 with treatment response, independent of age and gender. A predictive model was developed with 76.2% sensitivity and 91.9% specificity for estimating DAAs response in HCV patients.Our findings confirmed the IL28B rs12979860 T > C and FOXP3 rs2232365 A > G polymorphisms significantly affect DAA treatment response in HCV Egyptian patients. Lower levels of IL-28B along with higher levels of FOXP3 are linked to poor response. Our results may lead to new insights into DAA responsiveness contributing to personalized medicine and improving therapeutic decision-making for HCV patients. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsInterferonsPolymorphism, Single NucleotideInterleukinsForkhead Transcription FactorsHumansMaleFemaleMiddle AgedAdultEgyptTreatment OutcomePromoter Regions, GeneticImmunogeneticsInterferon Lambda

Stichwörter der Autor:innen

DAADaclatasvirFOXP3HCVIL28BSofosbuvir

Substanzen

Antiviral AgentsInterferonsinterferon-lambda, humanInterleukinsFOXP3 protein, humanForkhead Transcription FactorsInterferon Lambda

Autor:innen und Institutionen

  • Department of Research and Development, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
  • Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
  • Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt. samar_saad_azab@pharma.asu.edu.eg.

ORCID-Profile: Samar S Azab

Förderung

  • Ain Shams University

Zitieren

APA

Abdelaziz, A. I., Abdelsameea, E., Abdel-Samiee, M., Ghanem, S. E., Wahdan, S. A., Elsherbiny, D. A., Zakaria, Z., & Azab, S. S. (2024). Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01432-x

Vancouver

Abdelaziz AI, Abdelsameea E, Abdel-Samiee M, Ghanem SE, Wahdan SA, Elsherbiny DA, et al. Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01432-x

BibTeX
@article{Abdelaziz2024,
  author = {Abdelaziz, Aya Ismail and Abdelsameea, Eman and Abdel-Samiee, Mohamed and Ghanem, Samar E and Wahdan, Sara A and Elsherbiny, Doaa A and Zakaria, Zeinab and Azab, Samar S},
  title = {Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01432-x}
}
Kostenlos starten →